Maraviroc Intensification of cART in Patients with Suboptimal Immunological Recovery: A 48-Week, Placebo-Controlled Randomized Trial

OBJECTIVE: The immunomodulatory effects of the CCR5-antagonist maraviroc might be beneficial in patients with a suboptimal immunological response, but results of different cART (combination antiretroviral therapy) intensification studies are conflicting. Therefore, we performed a 48-week placebo-con...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:PLoS One
Main Authors: van Lelyveld, Steven F. L., Drylewicz, Julia, Krikke, Maaike, Veel, Ellen M., Otto, Sigrid A., Richter, Clemens, Soetekouw, Robin, Prins, Jan M., Brinkman, Kees, Mulder, Jan Willem, Kroon, Frank, Middel, Ananja, Symons, Jori, Wensing, Annemarie M. J., Nijhuis, Monique, Borghans, José A. M., Tesselaar, Kiki, Hoepelman, Andy I. M.
Formato: Artigo
Idioma:Inglês
Publicado em: Public Library of Science 2015
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4514679/
https://ncbi.nlm.nih.gov/pubmed/26208341
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0132430
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados